Elite Pharmaceuticals Inc (ELTP)

[Cognition]

03/27/14 talking about Barbara Ellison
"As an industry veteran, we expect that her national and INTERNATIONAL expertise in quality management and regulatory affairs will richly support our company's compliance and quality goals. We welcome her to our team."

08/06/13
Mr. Treppel recalls that Elite previously tried to license the once-a-day formulation in the European market and had found a partner. “At that time, we didn’t have the financial wherewithal to pursue that opportunity. It’s fair to say that that opportunity may get looked at again because there are opportunities overseas, especially the European and Asian markets for opioids.”

And Canada too!
03/10/14
Elite announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Note that last line. Additional patents pending in EUROPE too!

Only get one post a day.